Aesther Healthcare Acquisition Corp

Aesther Healthcare Acquisition Corp. is a blank check company, which engages in seeking a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Surendra Kumar Ajjarapu on June 17, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.

Ocean Biomedical Inc

Multiple Patents granted for Methods and Composition for Mono-specific and Bi-specific antibody approaches that suppress tumors by targeting and neutralizing elevated levels of chitinase 3-like-1 ( CH I 3L1 ) and other mediators .

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types

NEW YORK and PROVIDENCE, R.I, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (“SPAC”) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company, today announced that its stockholders approved all proposals related to the previously announced proposed business combination between Aesther and Ocean at a special meeting of stockholders held on February 3, 2023. A Form 8-K disclosing the full voting results is expected to be filed with the Securities and Exchange Commission.

Aesther and Ocean Biomedical Announce Shareholder Approval of Business Combination

NEW YORK and PROVIDENCE, R.I., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther's stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures regarding Excise Tax

Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Ocean Biomedical stock is expected to trade on the Nasdaq Capital Market under ticker symbol "OCEA"

Ocean Biomedical Provides Corporate Update and Company Summary

NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther's stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

New York, NY and Providence, RI, Dec. 16, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther representing the sum needing to be paid by Aesther to extend the date on which Aesther must consummate its initial business combination from December 16, 2022 to March 16, 2023.

Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination

New York, NY and Providence, RI, Dec. 13, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from December 16, 2022 to March 16, 2022 (the “Second Extension”), as permitted under Aesther's governing documents. In connection with the Second Extension, Aesther's sponsor, Aesther Healthcare Sponsor, LLC, has agreed to deposit an aggregate of $1,050,000 into Aesther's Trust account for its public stockholders, representing $0.10 per public share, by December 16, 2022, which will be in the form of a loan. Aesther's governing documents permit a total of two three-month extensions, of which this is the second.

Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination

• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”.

Novel Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical's Scientific Co-founder, Dr. Jake Kurtis, unveiling the potential for a new class of Antimalarial Drugs.

NEW YORK and PROVIDENCE, R.I., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (“SPAC”) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that Aesther has entered into two separate Backstop Agreements for a total of up to $80 million, with the addition of up to $40 million from Meteora Special Opportunity Fund I, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Capital Partners, LP (collectively, “Meteora”) in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean. Previously, Aesther had executed and announced an up to $40 million Backstop Agreement with Vellar Opportunity Fund SPV LLC-Series 3.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce Execution of a Second up to $40 Million Backstop Agreement, for a Total of up to $80 Million

• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp . and will change its name to Ocean Biomedical, Inc . , and is expected to be listed on NASDAQ under the symbol , “OCEA ”.

Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.

NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AHEA has filed with the U.S. Securities and Exchange Commission ("SEC") a preliminary proxy statement (“Preliminary Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

NEWS PROVIDED BY Aesther Healthcare Acquisition Corp (NASDAQ: AEHA)

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital

• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp . and will change its name to Ocean Biomedical, Inc . , expected to be listed on NASDAQ under the symbol , “OCEA ”.

Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)

New York, NY, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, or similar business combination with one or more businesses, today announced that it has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean Biomedical”), a next-generation biopharma company, (the “Merger Agreement”). The combined company will work to accelerate the development of Ocean Biomedical's core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million.

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Combined Company Expected to Trade on the NASDAQ Post-close under Ticker Symbol EVGT NEW YORK, NY / ACCESSWIRE / May 27, 2022 / Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA) ("Aesther"), a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced that it has entered into an Agreement and Plan of Merger (the "Merger Agreement") with United Gear & Assembly, Inc. ("United Gear"), a manufacturer of high precision gears for electric vehicles and other rapidly developing industries. Upon closing of the transaction, United Gear will be a wholly-owned subsidiary of Aesther (the "Business Combination").

Aesther Healthcare Acquisition Corp. and United Gear & Assembly, Inc. (High Precision Gears for Electric Vehicles) Announce Definitive Merger Agreement

News for Aesther Healthcare Acquisition Corp Stock (AEHA)